1. Home
  2. WGS vs ANIP Comparison

WGS vs ANIP Comparison

Compare WGS & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGS
  • ANIP
  • Stock Information
  • Founded
  • WGS 2017
  • ANIP 2001
  • Country
  • WGS United States
  • ANIP United States
  • Employees
  • WGS N/A
  • ANIP N/A
  • Industry
  • WGS Retail: Computer Software & Peripheral Equipment
  • ANIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • WGS Technology
  • ANIP Health Care
  • Exchange
  • WGS Nasdaq
  • ANIP Nasdaq
  • Market Cap
  • WGS 2.4B
  • ANIP 2.0B
  • IPO Year
  • WGS N/A
  • ANIP N/A
  • Fundamental
  • Price
  • WGS $139.62
  • ANIP $90.78
  • Analyst Decision
  • WGS Strong Buy
  • ANIP Strong Buy
  • Analyst Count
  • WGS 8
  • ANIP 7
  • Target Price
  • WGS $130.63
  • ANIP $99.14
  • AVG Volume (30 Days)
  • WGS 591.1K
  • ANIP 324.4K
  • Earning Date
  • WGS 10-28-2025
  • ANIP 11-07-2025
  • Dividend Yield
  • WGS N/A
  • ANIP N/A
  • EPS Growth
  • WGS N/A
  • ANIP N/A
  • EPS
  • WGS 0.07
  • ANIP N/A
  • Revenue
  • WGS $402,190,000.00
  • ANIP $747,399,000.00
  • Revenue This Year
  • WGS $39.54
  • ANIP $40.23
  • Revenue Next Year
  • WGS $22.50
  • ANIP $9.65
  • P/E Ratio
  • WGS $1,886.07
  • ANIP N/A
  • Revenue Growth
  • WGS 50.50
  • ANIP 38.68
  • 52 Week Low
  • WGS $55.17
  • ANIP $52.50
  • 52 Week High
  • WGS $146.00
  • ANIP $99.50
  • Technical
  • Relative Strength Index (RSI)
  • WGS 64.99
  • ANIP 45.10
  • Support Level
  • WGS $133.00
  • ANIP $89.47
  • Resistance Level
  • WGS $142.27
  • ANIP $95.57
  • Average True Range (ATR)
  • WGS 9.13
  • ANIP 3.14
  • MACD
  • WGS 1.23
  • ANIP -0.17
  • Stochastic Oscillator
  • WGS 83.67
  • ANIP 19.66

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: